Source: International Congress 2019 – Exploring exercise responses in respiratory diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Milne (Kingston, Ontario, Canada), M. Ibrahim-Masthan (Kingston, Ontario, Canada), A. Elbehairy (Kingston, Ontario, Canada), J. Neder (Kingston, Ontario, Canada), D. O’Donnell (Kingston, Ontario, Canada). Impact of nebulized fentanyl on exertional dyspnea in interstitial lung disease. 1632

Member's Comments

No comment yet.

Related content which might interest you: Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD Source: Eur Respir J 2004; 23: 832-840 Year: 2004 Uncovering the mechanisms of exertional dyspnoea in combined pulmonary fibrosis and emphysema Source: Eur Respir J, 55 (1) 1901319; 10.1183/13993003.01319-2019 Year: 2020 Mechanisms and consequences of exertional dyspnoea in combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2019 – Exercise physiopathology in various respiratory diseases Year: 2019 Heliox, dyspnoea and exercise in COPD Source: Eur Respir Rev 2009; 19: 30-38 Year: 2010 Fentanyl nasal spray in a patient with end-stage COPD and severe chronic breathlessness Source: Breathe, 15 (3) e122; 10.1183/20734735.0183-2019 Year: 2019 Safety in treating dyspnea with morphine in ILD patients Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018 Therapeutic saline inhalation: effects on lung function and dyspnoea in patients with chronic obstructive airway diseases Source: Eur Respir J 2001; 18: Suppl. 33, 484s Year: 2001 Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: 86-94 Year: 2004 Impact of anemia on dyspnea on exertion and exercise tolerance in patients with acute exacerbation of chronic obstructive pulmonary disease Source: Annual Congress 2011 - Exercise assessment in different diseases Year: 2011 Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease Source: Eur Respir J, 51 (1) 1701726; 10.1183/13993003.01726-2017 Year: 2018 Effects of long-acting bronchodilators on changes of inspiratory capacity by hyperventilation in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006 Effects of oxygen on exertional dyspnea and exercise performance in patients with COPD Source: Annual Congress 2011 - Clinical physiology for clinical problems Year: 2011 Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD Source: Eur Respir J 2001; 17: 1132-1137 Year: 2001 Exercise and dyspnoea in COPD Source: Eur Respir Rev 2006; 15: 72-79 Year: 2006 Effects of inhaled furosemide on exercise capacity and on dyspnea in patients with COPD Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Lung hyperinflation, dyspnoe, and exercise tolerance in patients with COPD exacerbation Source: Annual Congress 2010 - COPD exacerbation Year: 2010 Mechanisms of exertional dyspnoea in symptomatic smokers without COPD Source: Eur Respir J 2016; 48: 694-705 Year: 2016 Efficacy of long-acting bronchodilator inhalation on postoperative pulmonary function and quality of life in lung cancer patients with chronic obstructive pulmonary disease Source: Annual Congress 2008 - Actual challenges in thoracic surgery Year: 2008 Exertional dyspnoea and cortical oxygenation in patients with COPD Source: Eur Respir J 2015; 46: 1615-1624 Year: 2015 First dose response to tiotropium in COPD: Impact on dyspnea, lung hyperinflation and distal airways Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013